ZBIO — Stock Film
STOCK FILMSCENE 1/11ZBIO · $31.62
Stock Expert AI presents
ZBIO
Zenas BioPharma, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Zenas BioPharma, Inc. A quick introduction.

On the stock market since 2024, it operates in the world of health and science. It has 167 employees. Now — the numbers.

on the stock market since 2024
167 employees
$1.9B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $39.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$0
DEBT: $80.0M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
2 / 8
EXPECTATIONS MET OR BEATEN
2
Nov 2024
Apr 2025
May 2025
Aug 2025
Nov 2025
Mar 2026
May 2026
Aug 2026
2 TIMES IN THE LAST 8 QUARTERS
It misses the bar more often than not.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
9
very weak

Clearly below the class average.

FINANCIAL STRENGTH
54
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
27
very weak

Clearly below the class average.

GROWTH
33
very weak

Clearly below the class average.

PRICE MOMENTUM
79
strong

Clearly above the class average — a step short of the very top.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
Executives are buying stock10/10
WEAK SPOTS
Each sale is made at a loss3/10
Heavy bets against the stock3/10
WORTH WATCHING

Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 27% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
The product is selling

Sales run at $10M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 49 buys and 0 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $377.7M against $10M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, ZBIO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ZBIO is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film